Protocol Ledger

NCT04380961 · Phase II · COMPLETED

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Interventional Phase II clinical trial protocol NCT04380961 sponsored by Johnson & Johnson / Janssen in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-04-24 Enrollment: 212 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04380961
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)212 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04380961
Protocol FieldVerified Registry Value
NCT IdentifierNCT04380961
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment212 participants (ACTUAL)
Registered Start Date2020-04-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04380961
Hospital Research SiteLocationSite Profile
Loyola University Medical CenterMaywood, ILOpen Hospital Dossier ->
Henry Ford HospitalDetroit, MIOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI